5 completed. 5 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
| Phase 2 | 3 | Completed 3 |
Follow Refractory Marginal Zone Lymphoma: new trials by email Literature Review of Refractory Marginal Zone Lymphoma trials Research Report on Refractory Marginal Zone Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Lenalidomide, Obinutuzumab, Oral Azacitidine - Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Joseph Tuscano | 8 | 2020-10-23 | 2025-04-24 |
| Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma Carmustine, Cytarabine, Etoposide - Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 19 | 2018-09-10 | 2025-05-14 |
| Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma Blinatumomab, Lenalidomide - Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 35 | 2016-11-15 | 2025-11-26 |
| Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Obinutuzumab - Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 66 | 2014-05-27 | 2025-06-24 |
| Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma Bortezomib, Dexamethasone, Laboratory Biomarker Analysis - Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 9 | 2011-07-20 | 2021-10-04 |
Lymphoma, B-Cell, Marginal Zone (5) · Lymphoma, Follicular (5) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, Mantle-Cell (3) · Lymphoma, Non-Hodgkin (3) · Lymphoma, Large B-Cell, Diffuse (2) · Burkitt Lymphoma (1) · Leukemia, Hairy Cell (1) · Lymphoma, B-Cell (1) · Waldenstrom Macroglobulinemia (1)
Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Lymphoma (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Chronic Disease (4) · Disease Attributes (4) · Hematologic Diseases (4) · Leukemia (4) · Leukemia, B-Cell (4) · Leukemia, Lymphoid (4) · Lymphoma, B-Cell (4)
Lenalidomide (3) · obinutuzumab (2) · Azacitidine (1) · Bortezomib (1) · CT-P10 (1) · Calcium Dobesilate (1) · Carmustine (1) · Cytarabine (1) · Dexamethasone (1) · Etoposide (1) · Hematopoietic Stem Cell Transplantation (1) · Melphalan (1) · N,N-dicyclohexyl-isoborneol-10-sulfonamide (1) · Rituximab (1) · Sirolimus (1)
National Cancer Institute (NCI) (2) · Joseph Tuscano (1) · M.D. Anderson Cancer Center (1) · Ohio State University Comprehensive Cancer Center (1)
United States (5)
Joseph M Tuscano (2) · Kami Maddocks, MD (1) · Leonard T Heffner (1) · Loretta Nastoupil (1)
P30CA093373 (1), U10CA021115 (1), U10CA180820 (1), UM1CA186644 (1), UM1CA186717 (1)